Free Newsletter
Roche to change lobbyist stripes
The pharma-biotech dividing line just got a little fuzzier with Roche's plans to drop its membership in the Pharmaceutical Research and Manufacturers Association and sign on with the Biotechnology Industry Organization. After the big pharma's consumption of big biotech Genentech, the company finds that "Genentech and Roche believe BIO's purpose is closely aligned with the direction of the new company and, therefore, can represent the company's interest in Washington,'' spokeswoman Darian Wilson is quoted in a New Jersey Star Leger report. Article
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
